GlassScriptPhysician profile
Nathan G Miller
NPI 1265728166
$2,955.23
in general payments reported to CMS, 2019-2025
13 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $38.83 · 2021: $308 · 2022: $432 · 2023: $685 · 2024: $724 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.47 |
| Education | $356.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,029.66 | 2020-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $816.01 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $367.24 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $226.96 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $171.16 | 2023-2024 | Sotyktu |
| Almirall LLC | $130.49 | 2019 | |
| Ucb, INC. | $71.40 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $33.86 | 2023-2024 | Puraply Am, Puraply |
| Novartis Pharmaceuticals Corporation | $30.09 | 2019-2025 | |
| Biofrontera INC. | $25.35 | 2021 | |
| Dusa Pharmaceuticals, INC. | $21.72 | 2019 | |
| Sandoz INC. | $18.27 | 2024 | Hyrimoz |
| Pfizer INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.